3
50 Letters in Organic Chemistry, 2012, Vol. 9, No. 5
Li et al.
[
[
[
[
6]
7]
8]
9]
Politino, M.; Cadin, M. M.; Skonezny, P. M.; Chen, J. G. Process
for preparing dipeptidyl IV inhibitors and intermediates therefor.
WO. Patent 2005106011, October 11, 2005.
Godfrey J. D.; Jr.; Fox, R. T.; Buono, F. G.; Gougoutas, J. Z.;
Malley, F. M. Novel 1, 4-Homofragmentation via an r-Lactone. J.
Org. Chem., 2006, 71, 8647-8650.
Chongqing Medical University for partial financial support
of this work.
REFERENCES
Williams, E. L.; Zachary, L. A. Synthesis process for 2-(3-
[1]
Shubrook, J.; Colucci, R.; Guo, A.; Schwartz, F. Saxagliptin: a
selective dpp-4 inhibitor for the treatment of type 2 diabetes
mellitus. Med. Endocr. Diabetes, 2011, 4, 1-12.
hydroxy-1-adamantyl)-2-oxoacetic
006/0063950A1, May 23, 2006.
acid.
U.S.
Patent
2
Manchand, P. S.; Cerruti, R. J.; Martin, J. A.; Hill, C. H.; Merrett,
J, H.; Keech, E.; Belshe, R. B.; Connell, E. V.; Sim, L. S. Synthesis
and Antiviral Activity of Metabolites of Rimantadine. J. Med.
Chem., 1990, 33, 1992-1995.
Berner, M.; Partanen, R.; Salakka, A.; Somersalo, P. Process for
the perparation of adamantane derivatives. U.S. Patent 7205432B2,
April 17, 2007.
Kishi, A.; Kato, S.; Sakaguchi, S.; Ishii, Y. Catalytic radical
acetylation of adamantanes with biacetyl by a cobalt salt under
atmospheric dioxygen. Chem. Commum., 1999, 15, 1421-1422.
Yurchenko, A. G.; Fedorenko, T. V. Reaction or organomagnesium
compounds of the adamantane series with carbonyl compounds. J.
Org. Chem., USSR. 1987, 23, 875-880.
Rakhimov, A. I.; Cherepanov, A. A. Synthesis of methyl 1-
adamantyl ketone by electrochemical reduction of 1-
bromoadamantane in the presence of acetic anhydride. Russ. J.
Org. Chem., 2001, 37, 745-745.
[2]
Kim, Y. B.; Kopcho, L. M.; Kirby, M. S.; Hamann, L. G.; Weigelt,
C. A.; Metzler, W. J.; Marcinkeviciene, J. Mechanism of Gly-Pro-
pNA cleavage catalyzed by dipeptidyl peptidase-IV and its
inhibition by saxagliptin (BMS-477118). Arch. Biochem. Biophys.,
[10]
[11]
[12]
[13]
2
006, 445, 9-18.
[3]
Augeri, D. J.; Robl, J. A.; Betebenner, D. A.; Magnin, D. R.;
Khanna, A.; Robertson, J. G.; Wang, A.; Simpkins, L. M.; Taunk,
P.; Huang, Q.; Han, S. P.; Abboa-Offei, B.; Cap, M.; Xin, L.; Tao,
L.; Tozzo, E.; Welzel, G. E.; Egan, D. M.; Marcinkeviciene, J.;
Chang, S. Y.; Biller, S. A.; Kirby, M. S.; Parker, R.A.; Hamann,
L.G.. Discovery and preclinical profile of saxagliptin (BMS-
4
77118):ꢀ a highly potent, long-acting, orally active dipeptidyl
peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med.
Chem., 2005, 48, 5025-5037.
[
4]
5]
Kania, D. S.; Gonzalvo, J. D.; Weber, Z. A. Saxagliptin: a clinical
review in the treatment of type 2 diabetes mellitus. Clin Ther.,
2
011, 33, 1005-1022.
[
14]
15]
Pratt, D. G.; Rothstein, E. The elimination of carbon monoxide
from acid derivatives. Part III. Planar carbonium ions as necessary
intermediates. J. Chem. Soc. C., 1968, 2548-2554.
Stetter, H.; Rausher, E. Preparation of adamantine methyl ketone.
Chem. Ber., 1970, 103, 863-865.
[
Vu, T. C.; Brzozowski, D. B.; Fox, R. T.; Godfrey, J. D., Jr.;
Hanson, R. L.; Kolotuchin, S. V.; Mazzullo, J. A.; Patel, R. N.;
Wang, J.; Wong, K.; Yu, J.; Zhu, J. J.; Magnin, D. R.; Augeri, D.
J.; Hamann, L. G. Methods and compounds for producing
dipeptidyl peptidase IV inhibitors and intermediates thereof. U.S.
Patent 20050090539, April 28, 2005.
[